Adial Pharmaceuticals, Inc. (ADIL)
Chart Events
Performance Outlook
| Previous Close | 2.4900 |
| Open | 2.4500 |
| Bid | 2.3800 x 800 |
| Ask | 2.4200 x 1400 |
| Day's Range | 2.2400 - 2.4900 |
| 52 Week Range | 1.8500 - 5.0800 |
| Volume | |
| Avg. Volume | 204,708 |
| Market Cap | 52.157M |
| Beta (5Y Monthly) | 0.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0040 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.67 |
- Zacks
Is Adial Pharmaceuticals, Inc. (ADIL) Outperforming Other Medical Stocks This Year?
Here is how Adial Pharmaceuticals, Inc. (ADIL) and Albireo Pharma (ALBO) have performed compared to their sector so far this year.
- GlobeNewswire
Adial Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2022 Conference
CHARLOTTESVILLE, Va., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Chief Executive Officer of Adial, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022. Adial’s presentation will be available
- GlobeNewswire
Adial Pharmaceuticals Completes Private Placement of Common Stock at $4.00 Per Share
CHARLOTTESVILLE, Va., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has received the balance of $720,000 due from the $800,000 private placement previously disclosed by the Company on November 10, 2021 (the “Offering”). The shares of common stock sold in the Offerin
